Technology ❯ Biotechnology ❯ mRNA Technology

Lipid Nanoparticles

Covid-19 Vaccine Development Moderna's Vaccine Development DNA Delivery Systems COVID-19 Vaccines

NewLimit Raises $435 Million to Advance First Human Trial for Liver Rejuvenation

The capital will fund preparations for regulatory filings to test a transcription-factor therapy delivered by lipid nanoparticles in humans targeted for 2027.

3 ARTICLES

5mo ago

Lilly Acquires Engage Biologics for Up to $202 Million

15 ARTICLES

8mo ago

Moderna Reaches Up to $2.25 Billion LNP Patent Settlement, Pays $950 Million Upfront